June 7, 2011

The Healthcare Distribution Management Association on Monday awarded eight leading pharmaceutical and consumer product manufacturers through the presentation of its annual Distribution Industry Awards for Notable Achievements in health care.

June 7, 2011

Another generic drug maker has been given the green light to market its version of an Alzheimer's disease treatment.

June 6, 2011

The Food and Drug Administration has approved a dozen new generic versions of a drug used to treat breast cancer, the agency said Monday.

June 6, 2011

The Food and Drug Administration has found manufacturing issues at a plant owned by generic drug maker Impax Labs, the drug maker said Monday.

June 2, 2011

A class of drugs commonly used to control blood pressure does not increase patients’ risk of developing cancer, according to the Food and Drug Administration.

June 2, 2011

The Food and Drug Administration has approved a generic drug for Alzheimer’s disease made by Teva Pharmaceutical Industries.

June 1, 2011

The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

June 1, 2011

Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

June 1, 2011

The Food and Drug Administration has given orphan drug designation to an investigational treatment for multiple myeloma, a blood cell cancer, that soon will enter mid-stage development.

May 26, 2011

Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

May 26, 2011

Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.

May 26, 2011

Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.

May 25, 2011

Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

May 24, 2011

Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.

May 24, 2011

California-based companies are developing nearly more than one-fifth of the drugs to treat some of the deadliest diseases in the world, according to an analysis by the drug industry lobby.

May 24, 2011

The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

May 23, 2011

The summer 2011 Allergy Relief Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of such OTC allergy-symptom relievers as Claritin, Allegra, Zyrtec, Benadryl, Hyland's, Ocean, Similasan, Visine A.C. and Zaditor.

May 23, 2011

A generic drug maker has been granted approval from the Food and Drug Administration to manufacture its version of a urinary tract infection treatment.

May 23, 2011

Generic drug maker Par has inked a definitive agreement to acquire an India-based developer and manufacturer of generic drugs.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 20, 2011

The Food and Drug Administration has approved a new antiretroviral treatment for HIV made by Johnson & Johnson, the agency said Friday.

May 20, 2011

Sandoz is looking to market a generic version of a Shire drug for treating attention deficit hyperactivity disorder.

May 19, 2011

A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

May 18, 2011

Global spending on medicines will reach nearly $1.1 trillion by 2015, according to a new study by market research firm IMS Health.